Innovation versus complexity: what is too much of a good thing?

Harv Bus Rev

Bain & Company, Dallas, USA.

Published: November 2005

What's the number of product or service offerings that would optimize both your revenues and your profits? For most firms, it's considerably lower than the number they offer today. The fact is, companies have strong incentives to be overly innovative in new product development. But continual launches of new products and line extensions add complexity throughout a company's operations, and as the costs of managing that complexity multiply, margins shrink. To maximize profit potential, a company needs to identify its innovation fulcrum, the point at which an additional offering destroys more value than it creates. The usual antidotes to complexity miss their mark because they treat the problem on the factory floor rather than at its source: in the product line. Mark Gottfredson and Keith Aspinall of Bain & Company present an approach that goes beyond the typical Six Sigma or lean-operations program to root out complexity hidden in the value chain. The first step is to ask, What would our company look like if it made and sold only a single product or service? In other words, you identify your company's equivalent of Henry Ford's one-size-fits-all Model T-for Starbucks, it might be a medium-size cup of coffee; for a bank, a simple checking account-and then determine the cost of producing that baseline offering. Next, you add variety back into the business system, product by product, and carefully forecast the resulting impact on sales as well as the cost implications across the value chain. When the analysis shows the costs beginning to overwhelm the added revenues, you've found your innovation fulcrum. By deconstructing their companies to a zero-complexity baseline, managers can break through organizational resistance and deeply entrenched ways of thinking to find the right balance between innovation and complexity.

Download full-text PDF

Source

Publication Analysis

Top Keywords

innovation fulcrum
8
complexity
6
product
6
innovation
4
innovation versus
4
versus complexity
4
complexity good
4
good thing?
4
thing? what's
4
what's number
4

Similar Publications

Article Synopsis
  • The study evaluated the impact of a 6-month treatment with NP001, an immune modulator, on survival rates in patients with amyotrophic lateral sclerosis (ALS).
  • Based on data from 268 out of 273 participants in two clinical trials, the median overall survival (OS) increased by 4.8 months for those receiving NP001 compared to the placebo group, especially notable in patients aged 65 and under.
  • The results suggest that targeting inflammation via the innate immune system with NP001 could potentially offer new therapeutic approaches for ALS treatment.
View Article and Find Full Text PDF

Background: Cell-based strategies are being explored as a therapeutic option for muscular dystrophies, using a variety of cell types from different origin and with different characteristics. Primary pericytes are multifunctional cells found in the capillary bed that exhibit stem cell-like and myogenic regenerative properties. This unique combination allows them to be applied systemically, presenting a promising opportunity for body-wide muscle regeneration.

View Article and Find Full Text PDF

Niacin, an innovative protein kinase-C-dependent endoplasmic reticulum stress reticence in murine Parkinson's disease.

Life Sci

August 2024

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt.

Aims: Niacin (NIA) supplementation showed effectiveness against Parkinson's disease (PD) in clinical trials. The depletion of NAD and endoplasmic reticulum stress response (ERSR) are implicated in the pathogenesis of PD, but the potential role for NAD precursors on ERSR is not yet established. This study was undertaken to decipher NIA molecular mechanisms against PD-accompanied ERSR, especially in relation to PKC.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied how cis-regulatory elements (CREs) work with trans regulators to control the expression of T cell genes CD28, CTLA4, and ICOS, which are important for immune responses.
  • Using CRISPR interference (CRISPRi) screens, they identified specific CREs that vary depending on the type of T cell and stimulation, revealing the complexity of gene regulation.
  • They found that the CCCTC-binding factor (CTCF) plays a key role in enhancing the interaction between CREs and CTLA4 while also preventing unintended activation of CD28, helping to clarify the regulatory landscape of these immune genes.
View Article and Find Full Text PDF

Statocyst Ultrastructure in the Norwegian Lobster ().

Biology (Basel)

May 2024

Laboratory of Applied Bioacoustics, Universitat Politècnica de Catalunya, BarcelonaTech. Rambla Exposició s/n, 08800 Vilanova i la Geltrú, Barcelona, Spain.

Statocyst anatomy and fine morphology in Norwegian lobster () are studied for the first time using scanning and transmission electron microscopy. exhibits sensory setae projecting from the statocyst inner cavity floor into a mass of sand granules (statoconia) embedded in a gelatinous substance. The setae are distributed in four areas: a curved field made up of an inner single row and an outer double row that run on a circle around the medial and lateral rim of the central depression, a small setal field in the posterior part, a large setal field, opposite to the small field, and a short row, running internally and lying parallel to the inner single row, next to the small setal field.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!